Smart Australian Financial ETF (ASF)

Overview

Invex Therapeutics Ltd is a pioneering biopharmaceutical enterprise based in Perth, Australia, dedicated to the development of innovative treatments for neurological conditions characterized by elevated intracranial pressure. Since its inception in 2019, Invex has focused its efforts on addressing complex neurological disorders through rigorous research and development. The company has made significant strides in the field, notably reaching Phase III clinical trial status for its flagship treatment Exenatide. This achievement underscores Invex’s commitment to advancing medical science and offering new hopes for patients suffering from idiopathic intracranial hypertension, acute stroke, and traumatic brain injury, among other conditions.

Products and Services

• Exenatide for Neurological Conditions

  Invex Therapeutics Ltd is at the forefront of developing Exenatide, a treatment aimed at addressing neurological conditions associated with or resulting from elevated intracranial pressure. This therapeutic candidate has demonstrated promise through its successful advancement to a Phase III clinical trial, highlighting Invex's capability in leading a distinctive drug development pathway. Exenatide's role in the treatment of idiopathic intracranial hypertension, acute stroke, and traumatic brain injury positions it as a potentially transformative solution in the neurology sector. Through Exenatide, Invex endeavors to provide a novel treatment option that could significantly improve outcomes for patients grappling with these challenging conditions.